Oligodendrocytes are best known as the myelin builders of the central nervous system. They wrap neuronal axons in layered membranes of myelin, the fatty insulation that allows electrical signals to travel quickly and reliably, and they also supply metabolic support to the axons they ensheath. Each mature oligodendrocyte can myelinate segments of multiple axons at once, which makes these cells unusually demanding from a metabolic standpoint. Producing and maintaining myelin requires intense lipid synthesis, and lipid-rich membranes are notoriously vulnerable to oxidative damage. That vulnerability matters in Parkinson’s disease, where oxidative stress is considered one of the central destructive forces acting on the vulnerable neurons of the substantia nigra.

The research team, led by Fang Yan and Jie Bai of Kunming University of Science and Technology in China, set out to ask whether thioredoxin-1, a protein already known to protect dopaminergic neurons from the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, also influences the oligodendrocyte changes that unfold in the same model. MPTP, as the toxin is abbreviated, is a mainstay of experimental Parkinson’s research. Originally discovered after accidental exposure caused a Parkinson-like syndrome in human drug users, MPTP is converted in the brain into a toxic metabolite called MPP+ that is taken up selectively by dopaminergic neurons, where it sabotages mitochondria and floods cells with reactive oxygen species. The result is a reproducible loss of the same neuronal population that degenerates in patients, along with accumulation of alpha-synuclein.

Thioredoxin-1 sits at the heart of one of the cell’s principal antioxidant systems. It is a small protein that cycles between an oxidized and a reduced form, shuttling electrons to neutralize reactive oxygen species and to keep other protective enzymes, such as peroxiredoxins, in their active states. By maintaining the cellular redox balance, thioredoxin-1 protects proteins, lipids, and DNA from oxidative assault. Earlier work by the same research community had shown that the protein shields dopaminergic neurons from MPTP-induced neurotoxicity, and that it can reduce alpha-synuclein accumulation by promoting the autophagy-lysosome pathway, the cellular waste-disposal machinery that degrades misfolded proteins. The open question was whether these protective effects extend to the oligodendrocyte lineage.

To find out, the researchers treated mice with MPTP to induce Parkinson-like neurodegeneration and then examined the substantia nigra pars compacta, the region most affected in the disease. Using cell-type-specific markers, they tracked the full developmental sequence of the oligodendrocyte lineage: oligodendrocyte progenitor cells, which are the stem-like precursors capable of dividing and migrating; pre-myelinating oligodendrocytes, which have committed to maturation but have not yet wrapped axons; and mature oligodendrocytes, which carry out myelination. They also measured myelin thickness, a direct readout of the insulating capacity of the tissue, and they looked for alpha-synuclein inside oligodendrocytes as well as in dopaminergic neurons.

The findings were striking. Rather than being passively destroyed, the oligodendrocyte lineage responded to MPTP with a coordinated expansion. The number of oligodendrocyte progenitor cells increased, as did the numbers of pre-myelinating oligodendrocytes and mature oligodendrocytes, and myelin thickness in the substantia nigra also grew. This suggests that the myelinating compartment of the midbrain mounts an active, staged response to the toxic insult, ramping up both the production of new lineage cells and the deposition of myelin. Whether this response is protective, compensatory, or in some contexts harmful remains an open question, but its existence demonstrates that Parkinson-like pathology is not confined to neurons. The disease process, at least in this model, remodels an entire glial lineage.

Perhaps the most consequential observation concerned alpha-synuclein. The protein, famous for its role in the neuronal Lewy bodies that define Parkinson’s pathology, was found to accumulate in oligodendrocytes after MPTP treatment, not only in dopaminergic neurons. This is significant because in the human disease, a related condition called multiple system atrophy is characterized precisely by alpha-synuclein aggregates inside oligodendrocytes, known as glial cytoplasmic inclusions. The new data indicate that even in a classical Parkinson model, oligodendrocytes can become a reservoir for the misbehaving protein. Because oligodendrocytes provide metabolic support to neurons and maintain myelin, alpha-synuclein accumulation within them could compromise axonal health and contribute to the circuit dysfunction that produces the motor symptoms of the disease.

Crucially, thioredoxin-1 regulated all of these changes. In mice expressing or supplied with the redox protein, the MPTP-driven increases in oligodendrocyte lineage cells and myelin thickness were modulated, and the accumulation of alpha-synuclein in oligodendrocytes was likewise brought under control. In other words, a single antioxidant protein appears to influence both sides of the glial response: the proliferation and maturation dynamics of the oligodendrocyte lineage, and the protein aggregation burden within those cells. The authors interpret this as evidence that the oligodendrocyte alterations seen in MPTP-induced Parkinson’s mice are not incidental but are actively shaped by the cellular redox environment, and that thioredoxin-1 is a key regulator of that environment.

The mechanistic logic is plausible in light of what is known about both cell types. MPTP toxicity generates oxidative stress that would be expected to damage myelin membranes and to impair the protein quality-control systems that normally clear misfolded alpha-synuclein. Thioredoxin-1, by buffering reactive oxygen species and by supporting autophagy-lysosomal degradation, could simultaneously relieve the pressure that drives lineage expansion and the pressure that permits protein aggregation. If oligodendrocytes proliferate in response to myelin damage, reducing that damage at its source would reduce the perceived need for repair. If alpha-synuclein accumulates because clearance systems are overwhelmed, boosting those systems would restore balance. The study’s results are consistent with both mechanisms operating through a shared redox-sensitive hub.

For the Parkinson’s field, the work widens the therapeutic aperture. Most neuroprotective strategies have aimed squarely at dopaminergic neurons, and the idea of supporting oligodendrocytes has been explored mainly in the context of multiple sclerosis and other demyelinating diseases. This study suggests that in Parkinson’s disease, the myelinating cells of the substantia nigra are participants in the pathology and potential targets for intervention. A therapy that bolsters thioredoxin-1 activity, or mimics its effects, could in principle protect neurons and glia at the same time, addressing the oxidative stress and protein aggregation that cut across cell types. The researchers acknowledge that their findings come from the MPTP model, which reproduces key features of the disease but does not capture its full complexity, and that translating redox biology from mice to patients remains a formidable challenge. Still, the demonstration that a well-characterized antioxidant protein orchestrates the oligodendrocyte response to Parkinson-like injury adds a new dimension to a disease that science has been trying to see whole. The cells that insulate the brain’s wiring, it turns out, are not bystanders in Parkinson’s disease. They are players, and thioredoxin-1 may hold one of the controls.

Subject of Research: Effects of thioredoxin-1 on oligodendrocyte lineage cells and alpha-synuclein accumulation in an MPTP mouse model of Parkinson's disease

Article Title: Effects of thioredoxin-1 on oligodendrocyte lineage cells altered by the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Article References: Yan, F., Xia, Q., Sun, X., Duan, J., Gu, R., Pan, Y., Bai, L., Li, Y., Zhang, X., & Bai, J. (2026). Effects of thioredoxin-1 on oligodendrocyte lineage cells altered by the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01581-8

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01581-8

Keywords: Parkinson's disease, thioredoxin-1, oligodendrocytes, MPTP, alpha-synuclein, substantia nigra, myelin, oxidative stress, oligodendrocyte progenitor cells, neurodegeneration, redox biology, dopaminergic neurons

The review organizes the sprawling literature into five distinct propositions: redox control of telomerase activity, the reverse control of redox metabolism by the telomerase reverse transcriptase TERT, oxidative damage to telomeric DNA itself, redox-associated alternative lengthening of telomeres (ALT), and the therapeutic translation of all of the above. Each proposition is then graded separately for causal strength and molecular directness — two qualities the authors emphasize can vary completely independently. A finding can be causally robust yet mechanistically indirect, resting on a chain of downstream events; or it can be chemically precise yet demonstrated only in a test tube. Recognizing this independence, they contend, is the first step toward cleaning up a literature that has often graded studies on a single, misleading scale.

One of the sharpest methodological criticisms in the review targets a design that appears throughout the redox–telomerase literature: pretreating cells with millimolar concentrations of a thiol antioxidant such as N-acetylcysteine or glutathione before exposing them to a thiol-reactive electrophile. The problem, the authors explain, is one of chemical ambiguity. At those concentrations, the added thiol can simply quench the electrophile directly in the culture medium, a brute-force chemical reaction that has nothing to do with restoring the cell’s own antioxidant capacity. A rescue observed under those conditions cannot distinguish between genuine redox regulation of telomerase and trivial chemical neutralization of the insult. Because so many headline claims about antioxidants modulating telomerase rest on exactly this design, the finding casts a long shadow over a substantial fraction of the field.

What survives the audit? The authors identify the peroxide-driven, Src kinase–dependent phosphorylation of TERT at tyrosine 707, which triggers export of the enzyme from the nucleus via the Ran transport pathway, as among the best-supported redox findings. Hydrogen peroxide activates Src family kinases, phosphorylation at that specific residue promotes nuclear export, and the pathway satisfies necessity tests — blocking the kinase or the export machinery prevents the effect. Similarly well-supported is the glutathione depletion-and-repletion paradigm, in which lowering cellular glutathione alters telomerase activity and restoring it rescues the phenotype. Yet even these strongest findings, the review notes, remain pathway-mediated rather than chemically direct, and several were established in transfected systems or non-cancer cells such as endothelial cells and fibroblasts, leaving open questions about how faithfully they recapitulate events in an intact tumor.

Perhaps the most striking conclusion of the entire appraisal is a negative one. Despite decades of work, the authors identified no study that causally links a residue-resolved oxidative modification of endogenous TERT — a specific cysteine or tyrosine chemically modified by a defined reactive species inside a living cancer cell — to an altered outcome in telomerase assembly, subcellular localization, or catalytic activity. The distinction matters because redox biology has matured into a chemistry-first discipline: modern chemoproteomic tools can now identify which cysteines in a proteome are reactive, which ones get oxidized under defined conditions, and what functional consequences follow. TERT, with its multiple regulatory phosphorylation sites and its dependence on assembly with the telomerase RNA component, dyskerin and other partners, is precisely the kind of protein where such residue-level resolution should be achievable — and has not yet been delivered.

In contrast, the most molecularly direct chemistry in the entire field sits not on the protein but on the telomeric DNA itself. Guanine-rich telomeric repeats are exquisitely vulnerable to oxidation, and the review assembles a compelling body of biochemical work showing that the identity and position of an oxidative lesion govern nearly everything that matters: binding by the shelterin proteins TRF1 and TRF2, folding of the telomeric G-quadruplex structures that regulate telomerase access, recruitment of repair glycosylases such as OGG1 and the NEIL family, and the ability of telomerase to extend the chromosome end. An 8-oxoguanine lesion at one position of a G-quadruplex can destabilize the structure and promote telomerase extension, while the same lesion elsewhere blocks it — a position-dependent logic revealed through single-molecule and biochemical assays.

Even more provocative are recent findings showing that telomeric oxidation can drive dysfunction without any detectable shortening of the telomere. In work highlighted by the review, a single acute burst of targeted 8-oxoguanine damage at telomeres was sufficient to trigger rapid premature senescence, with telomere length remaining essentially unchanged. This decouples telomere dysfunction from the classical model in which telomeres erode gradually with each cell division, suggesting that a discrete oxidative event can flip the shelterin-bound chromosome end into a damage-signaling state essentially overnight. For cancer biology, the implication is double-edged: oxidative stress can push premalignant cells toward senescence, but it can also, under other conditions, push telomeres toward the recombination-based ALT pathway that a subset of tumors uses to elongate their chromosome ends.

On the therapeutic front, the review delivers a sobering translational parallel to its mechanistic gap. Imetelstat, the lipid-conjugated oligonucleotide that directly targets the telomerase RNA template, has now established randomized phase 3 efficacy in lower-risk myelodysplastic syndromes and has earned regulatory approval in the United States and a positive assessment in Europe. Yet the review points out that its redox engagement — whether the drug’s effects intersect with the oxidative stress programs that co-occur in treated tumors — has never been measured, nor have telomere pharmacodynamics been tracked in a way that connects clinical response to telomere biology at the molecular level. The most clinically successful telomerase-targeting agent, in other words, is as much of a black box with respect to redox as endogenous TERT is with respect to residue-level oxidation.

The review also surveys a crowded pipeline of redox-active agents with claimed telomerase effects: disulfiram and its copper diethyldithiocarbamate complex, which has been reported to induce both mitochondrial and telomerase dysfunction in lung cancer models; glutathione synthesis inhibitors such as butionine sulfoximine tested in combination regimens; the nucleoside analog 6-thio-deoxyguanosine, now in a phase 3 trial in non-small cell lung cancer, which recent structural work suggests stalls telomerase in a non-productive complex; and G-quadruplex ligands whose mechanisms have required substantial reevaluation. The authors’ framework provides a way to grade each of these claims, and the grades are frequently humbling: many rest on pharmacological exposures at concentrations far from physiological, in cell lines of uncertain provenance, with telomerase activity measured by the TRAP assay, which is itself known to be vulnerable to artifacts from redox-active compounds in the lysates.

What would close the gaps? The authors set out a concrete measurement agenda. For the protein side, it means deploying residue-resolved chemoproteomics and structural methods such as cryo-electron microscopy to catch endogenous TERT in the act of being oxidatively modified, and then testing causality with precisely engineered non-oxidizable mutants. For the telomere side, it means mapping lesion identity and position in cells, not just in synthetic oligonucleotides, and tracking how those lesions propagate through shelterin binding, repair, and telomerase extension. For the clinic, it means measuring telomere pharmacodynamics and redox biomarkers in imetelstat-treated patients. Until those measurements exist, the review concludes, the field should resist the temptation to narrate a tidy story of oxidants and telomeres — because the honest story, carefully audited, is one of strong chemistry at the chromosome end, plausible but unproven signaling at the enzyme, and a translational success whose deepest mechanisms remain to be written.

Subject of Research: Redox regulation of telomerase and telomeres in cancer

Article Title: Redox regulation of telomerase and telomeres in cancer: a critical appraisal of exposure, causality and molecular directness

Article References: Tatar, M., Khorrami, M., Kazemi, F., Masoumi, M., Babaei, S., & Khorrami, M. (2026). Redox regulation of telomerase and telomeres in cancer: a critical appraisal of exposure, causality and molecular directness. Molecular Biology Reports, 53(1), Article 1638. https://doi.org/10.1007/s11033-026-12826-3

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12826-3

Keywords: telomerase, TERT, telomeres, redox biology, oxidative stress, cancer, 8-oxoguanine, glutathione, ALT, imetelstat, DNA damage, G-quadruplex

Iron is essential for life, powering everything from oxygen transport to the electron transport chain in mitochondria, but it is also a double-edged element. When iron accumulates in the wrong form or the wrong place, it drives the Fenton reaction, generating hydroxyl radicals and other reactive oxygen species that damage DNA, proteins and lipids. This iron dyshomeostasis has been implicated in the aging process and in the pathogenesis of numerous neurodegenerative diseases, including Alzheimer’s disease, yet the underlying mechanisms remain largely unknown. In humans, multicopper ferroxidases such as ceruloplasmin and hephaestin convert toxic ferrous iron, Fe2+, into its safer ferric form, Fe3+, which can then be safely loaded onto transport and storage proteins. Whether the fly equivalent of these enzymes performs a similar protective role in the nervous system was an open question.

The research team, led by Minglin Lang of the University of Chinese Academy of Sciences and the College of Life Science at Agricultural University of Hebei, with Xuejiao Chang and Yudie Ma as co-first authors, set out to characterize MCO1’s function in vivo. In earlier work they had determined that MCO1 possesses dual catalytic activity, acting both as a ferroxidase and as an ascorbate oxidase, an enzyme that oxidizes vitamin C. The problem was that these two activities are chemically intertwined in the same protein, making it difficult to know which one matters physiologically. The new study combined a pan-neuronal elav-Gal4 driver for manipulating gene expression in neurons with the CRISPR-Cas9 gene-editing system to generate precisely targeted fly mutants, allowing the team to dissect the contributions of each activity to development, survival and locomotion.

The first clue that MCO1 is a genuine player in iron metabolism came from dietary experiments. When the researchers altered the iron content of the flies’ food, MCO1 expression responded in both the mid-gut and the brain, suggesting the gene is part of a regulated iron-sensing network rather than a bystander. Consistent with this, changing neuronal MCO1 levels significantly affected the expression of key iron metabolic genes, including Malvolio, the fly homolog of the mammalian divalent metal transporter DMT1, and the Transferrins, which encode iron-binding transport proteins. In other words, MCO1 does not merely respond to iron; it sits upstream of the machinery that governs how much iron the nervous system takes up and stores.

To test whether MCO1’s ferroxidase function is evolutionarily conserved, the team turned to yeast. Expressing MCO1 in yeast cells lacking Fet3, the ferroxidase component of the high-affinity iron uptake system, or lacking CCC2, a copper transporter required to load copper onto Fet3, partially rescued the mutant defects. The rescued cells also showed increased iron accumulation, indicating that MCO1 can functionally substitute for a canonical ferroxidase in a heterologous system. This cross-species complementation strengthened the argument that MCO1 is a bona fide member of the multicopper ferroxidase family rather than an enzyme with incidental iron chemistry.

The decisive experiments came from three CRISPR-Cas9 edited fly lines, each designed to impair a different aspect of MCO1’s chemistry. In the MCO1ΔExon IV mutant, deletion of a whole exon abolished both ferroxidase and ascorbate oxidase activities. In the MCO1D380A mutant, a single amino acid substitution at position 380, replacing an aspartate with alanine, specifically disrupted ferroxidase activity while leaving the ascorbate oxidase side of the enzyme intact. In the MCO1H374S mutant, a histidine-to-serine change at position 374 selectively eliminated ascorbate oxidase activity. This elegant trio allowed the researchers to attribute phenotypes to one activity or the other with unusual precision.

The results were striking. Flies lacking both activities, and flies lacking ferroxidase activity alone, accumulated ferrous iron and reactive oxygen species in their aging brains. The damage was not confined to molecular markers: these mutants showed severely impaired development, reduced locomotor performance and shortened lifespan. The D380A flies, in which one aspartate residue was swapped for alanine, recapitulated the full severity of the exon deletion, pinpointing D380 as the residue that makes ferroxidase activity possible. Because ferrous iron is the form that fuels radical production, the failure to oxidize Fe2+ to Fe3+ provides a direct mechanistic link between the enzyme’s active site and the oxidative damage observed in the aging brain.

The surprise came from the opposite direction. When the team eliminated ascorbate oxidase activity alone in the H374S mutant, ferrous iron accumulation was suppressed rather than worsened, and the flies lived substantially longer than normal. This suggests that the two activities of MCO1 are not simply redundant partners but competing forces: the ascorbate oxidase function, which consumes vitamin C, may undermine the antioxidant capacity of the nervous system, while the ferroxidase function detoxifies iron. In the H374S flies, preserving ascorbate appears to tip the redox balance toward protection, extending lifespan without the developmental costs seen in the other mutants.

The technical approach underlying these findings deserves attention in its own right. By pairing tissue-specific Gal4 drivers with CRISPR-edited alleles, the team could distinguish between effects of MCO1 in neurons and effects elsewhere, using quantitative PCR to track iron metabolic genes, colorimetric and fluorescent probes such as dichlorofluorescein diacetate to measure iron species and reactive oxygen species, and standard assays of development, climbing ability and survival. Replicate experiments confirmed the critical role of the D380 residue in development and lifespan, and complete statistical analyses were made available in supplementary tables, reflecting the open-access ethos of the journal.

For the broader field, the study offers a compelling proof of principle that neural iron homeostasis can be genetically tuned at the level of a single amino acid, and that doing so changes how long an organism lives. Iron dyshomeostasis is a hallmark of aging human brains and of diseases such as Alzheimer’s, where excess iron and oxidative stress feed a self-reinforcing cycle of neuronal damage. If mammalian multicopper ferroxidases such as ceruloplasmin are governed by similar structure-function rules, the D380 and H374 positions of MCO1 may point toward residues whose modification could tilt the balance between iron detoxification and antioxidant depletion. The fly work does not yet translate into a therapy, but it identifies ferroxidase activity as a vital, druggable-looking node in the nervous system’s iron economy, and it suggests that modulating the dual activities of multicopper oxidases could become a strategy for slowing brain aging and the progression of neurodegenerative disease.

Subject of Research: The role of the MCO1 ferroxidase residue D380 in regulating neural iron homeostasis, oxidative stress and lifespan in Drosophila

Article Title: The D380 residue in MCO1 regulates neural iron homeostasis and fitness in Drosophila

Article References: Chang, X., Ma, Y., Jiang, S., Gao, H., Xu, R., Ullah, I., & Lang, M. (2026). The D380 residue in MCO1 regulates neural iron homeostasis and fitness in Drosophila. BMC Biology. https://doi.org/10.1186/s12915-026-02733-1

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02733-1

Keywords: MCO1, ferroxidase, iron homeostasis, Drosophila melanogaster, neurodegeneration, reactive oxygen species, ascorbate oxidase, CRISPR-Cas9, aging, lifespan, multicopper oxidase, redox biology

The two proteins in question are PARK7, also known as DJ-1, and PINK1. Both are best known to the public through their connection to familial Parkinson’s disease, where loss-of-function mutations sensitize neurons to oxidative damage and mitochondrial dysfunction. In the new work, the Tsukuba team asked whether these same proteins do something entirely different in a very different cellular context: the dramatic transformation that occurs when mouse embryonic fibroblasts are pushed toward pluripotency by reprogramming factors. PARK7 is a multifunctional, redox-sensitive protein long implicated in buffering oxidative stress and modulating transcription, and earlier reports had suggested it could associate with the promoter of Nanog, a master gene of pluripotency, and even suppress reprogramming efficiency. That hint of an inhibitory role made PARK7 an intriguing suspect.

To test the idea, the researchers depleted Park7 in mouse embryonic fibroblasts undergoing reprogramming and monitored the emergence of Nanog-positive colonies, a standard readout of successful pluripotency induction. The result was striking: knocking down Park7 enhanced colony formation, with the effect most pronounced during the early phases of reprogramming. In other words, removing PARK7 made it easier for somatic cells to cross the initial barriers on the road to pluripotency. This positioned PARK7 not as a passive bystander but as an active regulator of the process, and it raised the obvious question of how a protein best known for antioxidant defense could, when removed, actually improve the efficiency of cellular rejuvenation.

The answer, it turns out, lies in reactive oxygen species. Reprogramming is metabolically traumatic: a cell that has spent its life burning glucose efficiently through mitochondrial oxidative phosphorylation must tear down and rebuild its entire energy economy, ultimately adopting the glycolytic, lactate-producing metabolism characteristic of embryonic stem cells. That transition is accompanied by bursts of reactive oxygen species, which at controlled levels act as signaling molecules that help drive the switch. Using paused iPSCs, a valuable experimental system in which cells are held in a partially reprogrammed state and can be interrogated in detail, the team showed that depleting Park7 increased both mitochondrial and cytosolic ROS, stabilized HIF-1α, the hypoxia-inducible transcription factor that commands the glycolytic program, promoted the expression of glycolytic genes, and upregulated pluripotency markers.

The causal chain became clear when the researchers added antioxidants to the culture. Antioxidant treatment substantially blunted all of these effects, indicating that the enhanced reprogramming phenotype seen upon Park7 loss was driven by ROS-mediated metabolic remodeling rather than by some unrelated function of the protein. In essence, PARK7 normally keeps a brake on ROS levels, and that brake, paradoxically, restrains the very oxidative signals that help push a cell toward pluripotency. When the brake is released, ROS rise, HIF-1α accumulates, glycolysis genes switch on, and the cell slides more readily into its new pluripotent identity. It is a vivid demonstration that in reprogramming, a little oxidative stress is not the enemy but an ally.

The study also uncovered a second, compensatory layer of redox regulation. The elevated ROS triggered by Park7 depletion activated NRF2, the master transcription factor of antioxidant defense, switching on NRF2-dependent antioxidant transcriptional programs. This reveals a built-in feedback loop: as ROS climb and drive metabolic remodeling, the cell simultaneously mounts a protective antioxidant response, presumably to keep the oxidative surge within tolerable limits. The interplay between these pro-signaling and protective arms of the redox system highlights how finely balanced the reprogramming environment must be, and it suggests that manipulating this balance could be a way to tune reprogramming efficiency in the laboratory.

Perhaps the most consequential discovery, however, concerns PINK1. The team found that Park7 depletion reduces the expression of Pink1, and that knocking down Pink1 phenocopies the loss of Park7, producing the same ROS elevation, metabolic shift, and pluripotency marker upregulation. Most tellingly, restoring wild-type PINK1 reversed the increase in pluripotency markers caused by Park7 loss. Together, these experiments establish PINK1 as the essential downstream mediator of PARK7 in this cascade. The two Parkinson’s-linked proteins, it appears, operate as a functional axis: PARK7 upstream, sustaining PINK1 expression, and PINK1 downstream, executing the ROS-suppressing and metabolic functions that keep reprogramming in check.

This PARK7–PINK1 axis is more than a curiosity of stem cell biology. It suggests that the same molecular machinery whose failure contributes to neurodegeneration also serves as a gatekeeper during the acquisition of pluripotency, coordinating three intertwined processes: suppression of reactive oxygen species, glycolytic metabolic remodeling, and the expression of pluripotency genes. For researchers trying to generate iPSCs more efficiently and more safely, the findings point to concrete levers. Modulating PARK7 or PINK1 activity, or carefully titrating ROS with antioxidants, could in principle shift cells along the reprogramming trajectory. At the same time, the work cautions that redox manipulation is a double-edged sword, since the NRF2 response shows the cell actively defending itself against the very signals that promote its transformation.

There are also broader implications for understanding disease. PARK7 and PINK1 are central figures in the mitochondrial quality control literature, and this study ties them to HIF-1α-driven metabolic switching and NRF2-mediated antioxidant transcription, linking several of the most important stress-response pathways in cell biology into a single regulatory circuit. Whether the axis operates similarly in human cells, and whether it influences the quality and genomic stability of the resulting iPSCs, are questions the field will now want to pursue. The experiments were conducted in mouse embryonic fibroblasts and paused iPSCs, so translating the mechanism to human reprogramming systems will be an essential next step.

What the study delivers today is a mechanistic framework with immediate experimental value. By showing that PARK7 restrains reprogramming primarily through PINK1-dependent control of ROS, the Tsukuba team has converted a long-standing puzzle about DJ-1’s role at the Nanog promoter into a coherent signaling pathway that connects redox balance, metabolism, and gene expression during one of biology’s most dramatic cellular transformations. As regenerative medicine moves closer to the clinic, understanding such gatekeepers, and learning when to release them and when to respect them, may prove as important as the reprogramming factors themselves. The full open-access study is available in Cellular and Molecular Life Sciences for readers who wish to explore the experimental details.

Subject of Research: The role of the PARK7–PINK1 axis in redox balance and metabolic remodeling during induced pluripotent stem cell reprogramming

Article Title: A PARK7–PINK1 axis coordinates redox balance and metabolic remodeling during somatic cell reprogramming

Article References: Mensah, E. O., Burramsetty, A. K., Kamata, H., Jiang, Z., Fukuda, A., Hisatake, K., & Nishimura, K. (2026). A PARK7–PINK1 axis coordinates redox balance and metabolic remodeling during somatic cell reprogramming. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06468-8

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06468-8

Keywords: PARK7, DJ-1, PINK1, iPSCs, reprogramming, pluripotency, reactive oxygen species, HIF-1α, NRF2, metabolic remodeling, redox biology, mitochondria

The study, published in Nature Chemical Biology, describes a systematic pipeline in which human cells were treated with a library of small molecules while perturbing a broad panel of genes known to participate in genome maintenance. Each combination produced a measurable fitness signature—a fingerprint of viability, growth, and survival under stress. When those fingerprints were arranged into network form, they resolved into a chemogenomic map: a topological landscape in which drugs with similar mechanisms cluster together, and in which genes with related functions occupy neighboring positions. Such maps have proven their worth in cancer pharmacology before, where they revealed drug targets and resistance pathways that no one could have predicted from single-gene studies alone.

What makes the new analysis distinctive is its focus on the DNA damage response, the elaborate signaling network that detects broken strands of DNA, halts the cell cycle, coordinates repair machinery, and decides whether a damaged cell should live or die. Because so many cancer therapies—radiation, platinum drugs, topoisomerase inhibitors, PARP inhibitors—work by inflicting DNA damage, understanding the vulnerabilities and redundancies of this network is not an abstract scientific goal. It is a question that directly shapes treatment outcomes for millions of patients.

As the team clustered the chemical profiles, one signal kept surfacing. Compounds that disturb iron homeostasis—iron chelators that sequester the metal, and agents that expand the labile iron pool inside cells—produced genetic interaction patterns strikingly similar to compounds known to generate oxidative DNA damage. That convergence pointed to a mechanistic link: iron, through its well-documented role in Fenton chemistry, converts ordinary peroxide into hydroxyl radicals, the most destructive of the reactive oxygen species. Hydroxyl radicals attack DNA indiscriminately, producing strand breaks and oxidized bases that tax the same repair pathways mobilized by radiation and chemotherapy.

The linchpin of that link turned out to be peroxiredoxin 1, or PRDX1, a highly abundant enzyme whose canonical job is to detoxify peroxides inside the cell. Chemogenomic analysis showed that when PRDX1 function was compromised, cells became exquisitely sensitive to perturbations of iron metabolism. The map essentially revealed a dependency: iron-driven oxidative chemistry creates a peroxide burden, and PRDX1 is the gatekeeper that keeps that burden from escalating into lethal DNA damage. In cells with intact PRDX1, fluctuations in iron levels were tolerable; in cells lacking it, the same fluctuations translated into accumulating genome injury.

That discovery reframes PRDX1 from a general antioxidant housekeeper into a specific node of the DNA damage response. The enzyme, a member of the peroxiredoxin family of cysteine-based peroxidases, cycles between oxidized and reduced states as it destroys peroxide substrates. Its abundance in the nucleus and cytosol has long puzzled researchers—why does a cell need so much of it? The chemogenomic data suggest an answer in the language of vulnerability: PRDX1 provides the protective margin that allows cells to tolerate the continuous, low-level oxidative chemistry that accompanies normal metabolism, and that margin becomes decisive when DNA damage pushes iron-dependent radical production upward.

The iron-damage axis also has a darker face. In recent years, the cell biology community has converged on ferroptosis, a form of regulated cell death driven by iron-catalyzed lipid peroxidation, as a process with intimate ties to genome stress. The new map does not simply confirm that connection; it locates it within the broader architecture of the DNA damage response, showing that the same network that activates ATM and ATR kinases, deploys BRCA proteins, and summons the homologous recombination machinery is functionally coupled to peroxide metabolism and iron availability. Damage sensing and redox sensing, the map implies, are not separate systems but interlocking ones.

For oncology, the implications are immediately tantalizing. Many tumor types accumulate excess iron and rely heavily on antioxidant systems to survive their own metabolic output—a combination that makes them theoretically vulnerable to any therapy that removes their peroxide defense. If PRDX1 occupies that protective position in the iron-damage axis, then inhibiting it in an iron-rich tumor could tip the balance toward catastrophic, irreparable genome damage. Conversely, normal cells with lower labile iron loads might tolerate a PRDX1 inhibitor far better, creating the kind of therapeutic window that targeted therapy developers dream about. The chemogenomic framework makes such hypotheses testable at scale: rather than asking whether a single drug kills a single cell line, researchers can now ask where any new agent falls within the network of known damage-response dependencies.

The methodology itself deserves attention as a template. Chemogenomic mapping has matured into a discipline where perturbation libraries, high-content fitness assays, and computational embedding of interaction profiles generate maps with genuine predictive power. In this study, the authors systematically cross-referenced compound sensitivity profiles with gene perturbation data, using network inference to identify edges that classical pairwise screens would have missed. The PRDX1–iron connection is a proof of concept that such maps can surface biology that sits outside the conventional textbook divisions of the field—redox biochemistry emerging from a screen nominally designed to probe DNA repair.

There are, of course, caveats. Chemogenomic interactions describe statistical dependencies, and translating them into molecular mechanisms requires direct biochemical validation: measuring hydroxide radical generation, quantifying PRDX1 oxidation states during the damage response, and testing whether iron manipulation truly sensitizes PRDX1-deficient cells through the accumulation of double-strand breaks. The interaction maps are a hypothesis-generating engine, not a substitute for mechanism. But the strength of the approach lies precisely in its breadth—it surveys the whole terrain before anyone commits to digging a single hole, and it does so in a human cell context directly relevant to disease.

What emerges is a changed mental picture of genome maintenance. The DNA damage response has traditionally been drawn as a signaling diagram: kinases, adaptors, repair factors, and checkpoints connected by activation arrows. The chemogenomic map adds a chemical dimension to that diagram, weaving in iron pools, peroxide fluxes, and peroxidase capacity. A cell’s ability to survive a DNA break, in this view, depends not only on how fast it can find and repair the lesion but also on how well its redox buffers can contain the oxidative fallout that follows. PRDX1, sitting at the junction of those two requirements, now looks less like a background antioxidant and more like a strategic asset in the cell’s genome defense—raising the question of whether the next generation of cancer therapies will deliberately target the iron-damage axis to finish off tumors that have already been weakened by standard DNA-damaging treatment.

Subject of Research: A chemogenomic interaction map identifying a PRDX1-dependent axis linking iron metabolism and oxidative damage in the DNA damage response.

Article Title: Chemogenomic maps reveal a PRDX1-dependent iron–damage axis in the DNA damage response

Article References: O’Loughlin, T. A., Arab, A., Misiukiewicz, S., Montesano, E., Yogodzinski, C., Borah, A. A., Quarantotti, V., Lou, K., Rosen, B. S., Corn, J. E., Gianni, D., Kabir, S., Forment, J. V., & Gilbert, L. A. (2026). Chemogenomic maps reveal a PRDX1-dependent iron–damage axis in the DNA damage response. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02312-z

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02312-z

Keywords: chemogenomics, DNA damage response, PRDX1, peroxiredoxin 1, iron metabolism, ferroptosis, reactive oxygen species, Fenton chemistry, genome maintenance, cancer therapy, redox biology, Nature Chemical Biology

The central paradox the authors confront is chemical. ROS—including superoxide, hydrogen peroxide and hydroxyl radicals—are inherently reactive, which is precisely why uncontrolled ROS production is toxic. Yet evolution has exploited this very reactivity. Hydrogen peroxide, in particular, is small, electrically neutral and membrane-permeable, allowing it to diffuse rapidly through tissue and act as a broadcast signal. At wound margins, ROS can oxidize the cysteine residues of target proteins, reversibly altering the activity of phosphatases, kinases and transcription factors. In this way, a transient oxidative pulse functions as a second-messenger system, converting the physical fact of injury into a coordinated genetic and cellular response. The review frames this as oxidative eustress—beneficial, regulated stress—as opposed to the destructive oxidative distress associated with pathology.

What makes the new synthesis compelling is its comparative breadth. The authors assemble evidence spanning the metazoan tree, from cnidarians such as Hydra and Nematostella, which can rebuild entire bodies from small fragments, to planarian flatworms, annelids, echinoderms, fish, amphibians and mammals. In nearly every regenerative model examined, pharmacological or genetic suppression of ROS production—most often by blocking the NADPH oxidase enzymes, or NOXes, that generate superoxide at the wound—impairs regeneration. Conversely, exogenous hydrogen peroxide can, in some systems, partially rescue defective regenerative responses. The consistency of this pattern across such distantly related animals raises the tantalizing possibility that ROS signaling is not a collection of independent evolutionary accidents but a deeply rooted, possibly ancestral, component of the regeneration program.

The review is careful, however, to emphasize that conserved does not mean uniform. The regulatory roles and modes of action of ROS vary considerably among species, tissues and regenerative contexts. In some animals, ROS act primarily in the earliest wound-healing phase, recruiting immune cells and initiating proliferation; in others, oxidative signals persist into blastema formation, the mass of progenitor cells from which the new structure grows. The downstream targets differ as well: ROS have been implicated in activating Wnt, FGF, ERK and JNK signaling pathways, in modulating apoptosis, and in shaping the extracellular matrix, but the specific wiring differs from one organism to the next. This variability, the authors argue, is precisely why continued comparative study is essential. Only by mapping ROS involvement across many species can researchers distinguish genuinely common mechanisms from species-specific embellishments.

This comparative logic carries the review into deeper evolutionary waters. The evolutionary history of regeneration remains one of the great unresolved puzzles in biology. Why can a salamander regrow an entire limb while a mouse cannot? Why do some annelids regenerate their whole posterior body axis while closely related species fail at the same task? Two competing frameworks dominate the field: regeneration as an ancestral capacity repeatedly lost in lineages that traded it for other advantages, or regeneration as a trait independently gained, assembled from pre-existing wound-healing and developmental machinery. The authors argue that ROS data can inform this debate. If ROS signaling sits at the base of regenerative responses across the animal tree, it may represent an ancient, conserved layer of the process—one that lineages with poor regenerative abilities have not necessarily lost, but perhaps fail to deploy correctly.

That reframing has direct therapeutic implications, and it is here that the review makes its most forward-looking argument. Humans regenerate well in the liver, moderately in skin and bone, and hardly at all in the heart, spinal cord and limbs. If ROS signaling is a conserved trigger of regenerative programs, then modulating redox state could offer a lever to reactivate latent regenerative capacity in poorly regenerating human tissues. The concept is not fanciful. Studies in zebrafish and axolotl have shown that adjusting ROS levels can influence heart regeneration and appendage regrowth, and redox-sensitive pathways such as ERK and Wnt are already major targets of regenerative medicine research. The review suggests that a rigorous understanding of when, where and at what concentration ROS act could enable precisely timed redox interventions—boosting regeneration without tipping tissues into the oxidative damage that fuels fibrosis, inflammation and cancer.

The authors are equally candid about the obstacles. ROS are fleeting, highly reactive and difficult to measure with spatial and temporal precision, and many of the tools used to manipulate them—broad-spectrum antioxidants, generic NOX inhibitors—are blunt instruments with off-target effects. To address this, the review includes a supplementary compendium of the functional tools available to modulate ROS production in regeneration studies, cataloguing the main pharmacological inhibitors and activators as well as the principal targets for RNA interference, morpholino and knockout approaches. Standardizing and refining this toolkit, the authors contend, is a prerequisite for the field’s maturation. Without it, discrepancies between studies may reflect technical artifacts rather than genuine biological differences, muddying the comparative analyses on which evolutionary conclusions depend.

The review also identifies major knowledge gaps that will shape the next decade of work. The precise molecular targets of ROS during regeneration remain incompletely defined in most models; the dose, duration and gradients of oxidative signals at wounds are poorly quantified; and the interplay between ROS and other injury-induced signals—calcium fluxes, bioelectric gradients, mechanical forces and immune-derived cytokines—is only beginning to be explored. Another open question is whether ROS participate in the establishment of positional memory, the information that tells a regenerating blastema whether to build a hand, a tail or a head. Answering these questions will require combining live redox biosensors, genetic models and comparative approaches across species that span the breadth of regenerative ability, from master regenerators to refractory ones.

What emerges from the synthesis is a view of regeneration as a redox-gated process whose ancient logic may still be latent within our own cells. The authors, based at institutions including Université Paris Cité, Université Côte d’Azur, the University of Manchester, Sorbonne Université and École Normale Supérieure, argue that studying ROS across metazoan diversity serves a dual purpose: it illuminates how regeneration evolved, and it reveals why some species, including our own, regenerate poorly. Both lines of inquiry converge on the same practical prize—new strategies in regenerative medicine grounded in evolutionary insight rather than trial and error. If the oxidizing burst that follows injury truly is a conserved call to rebuild, then learning to read, and perhaps to amplify, that ancient signal could one day help human tissues do what salamanders have done for millions of years: grow back.

Subject of Research: The role of reactive oxygen species signaling in animal regeneration and its evolutionary and therapeutic implications

Article Title: Understanding ROS signaling and evolution during animal regeneration offers promising opportunities for novel therapeutic approaches

Article References: Vullien, A., John, J., Rampon, C., Amaya, E., Röttinger, E., & Gazave, E. (2026). Understanding ROS signaling and evolution during animal regeneration offers promising opportunities for novel therapeutic approaches. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06392-x

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06392-x

Keywords: reactive oxygen species, ROS signaling, regeneration, regenerative medicine, oxidative eustress, NADPH oxidase, evolutionary developmental biology, blastema, wound healing, redox biology, hydrogen peroxide, comparative biology